Airbus Launches Airspace Link HBCplus – The Flexible High Bandwidth Connectivity Solution for Airlines
14.6.2022 12:30:00 EEST | Business Wire | Press release
Airbus has launched Airspace Link HBCplus, its new flexible satellite connectivity solution that will be offered as an SFE* line-fit catalogue option and also for retrofit on all Airbus programmes. HBCplus, which initially encompasses Ka-band services, will enable airlines to connect to a choice of Managed Service Providers (MSPs) via a new certified terminal and radome built as part of the aircraft. In the future it is planned to extend HBCplus to include MSPs which offer Ku-band services.
Andre Schneider, Airbus VP Cabin & Cargo Programme said: “We are excited to offer airlines a new connectivity service solution that will provide improved speed and reliability for passenger experience and more flexibility. Together with our leading industry partners we are pleased to enable future connectivity business opportunities in the context of the Airspace Link open ecosystem.”
To this end Airbus has selected connectivity satcom leader Inmarsat as the first MSP, contributing its GX Aviation inflight broadband solution which offers reliable and seamless passenger experience with global coverage and capacity for future growth. Additional MSPs will join the HBCplus offering in due course.
Philippe Carette, President of Inmarsat Aviation, said: “We are honoured that Airbus has chosen Inmarsat as the first Managed Service Provider for this transformative connectivity catalogue solution and is putting its trust in our award-winning GX Aviation service across all of its aircraft programmes. Inmarsat looks forward to working closely with our partners Airbus and SPI to deliver continuous innovation for airlines and their passengers worldwide.”
Meanwhile Safran Passenger Innovations (SPI) has been selected as the terminal provider and hardware integrator of ThinKom’s proven antenna technology - targeted for Ka-band services which delivers high data throughput and reliability combined with aircraft fuel savings thanks to the antenna’s lower drag radome.
Matt Smith, CEO, Safran Passenger Innovations, said: “Safran Passenger Innovations is delighted to be selected as the equipment supplier for Airbus’ Airspace Link connectivity solution. We are excited to be a part of the next evolution in the IFC industry by providing the technology for airlines to select the connectivity services most suited to their needs. We look forward to working with Airbus and our partners on this industry-changing endeavour.”
Airspace Link HBCplus thus provides satcom based off-board connectivity for the Airspace Link open ecosystem representing an end-to-end Airbus offer. This solution, which enables the exchange of data as one seamlessly integrated aircraft system, is ideally positioned to unlock future digital services capacity and demand growth, allowing airlines to deliver a best in class passenger connectivity experience, in an exponentially growing market.
SFE* = Supplier Furnished Equipment
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005572/en/
Contact information
Martin FENDT
Airbus
+33 (0)6 29 54 27 03 martin.fendt@airbus.com
Lois BENQUET
Airbus
+33 (0)6 42 88 10 65 lois.benquet@arbus.com
Jared SIQUELAND
Safran Passenger Innovations
+1 714 203 0525 jared.siqueland@zii.aero
Robeel HAQ
Inmarsat Aviation
+44 (0)207 728 1352 robeel.haq@inmarsat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom